DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025" report to their offering.
The PD-1 and PD-L1 inhibitors market is estimated at $4,926.4 million in 2016, and it is expected to grow at a CAGR of 23.4% during 2017 - 2025.
The increased investment and funding, strong pipeline, technological advancements and innovations, high prevalence of cancer, and improved safety and efficacy are the key factors driving the growth of global market. Different companies are developing PD-1 and PD-L1 inhibitor drugs by using innovative techniques such as combination therapy and biomarkers. In combination therapy approach, PD-1 and PD-L1 inhibitors combine with all types of molecules such as monoclonal antibodies, vaccines, small molecule and cell therapies. The two therapies given together are more effective and powerful as compared to single immunotherapy. This will significantly drive the growth of the global PD-1 and PD-L1 inhibitors market.
Globally, Opdivo was the largest selling drug among the different PD-1 and PD-L1 inhibitor drugs in 2016. The global Tecentriq sale is expected to grow at a good rate during the forecast period to become the second largest selling drug in the global market by the end of 2024, overtaking Keytruda.
The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs and there are approximately 245 active clinical studies. The pipeline of PD-1 and PD-L1 inhibitors has been analyzed based on their mechanism of action (MOA). It was found that around 74% of pipeline molecules acts as PD-1 inhibitors and 26% of pipeline molecules as PD-L1 inhibitors. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including phase III, phase II, phase I and preclinical stage.
The increased use of combination therapy of PD-1 and PD-L1 inhibitors represent a new signal of immunotherapeutic, which is expected to alter the standard of care for cancer across the globe. In November 2016, Bristol-Myers Squibb Company and Infinity Pharmaceuticals collaborated to check the efficacy of combination of Opdivo (a PD-1 inhibitor monoclonal antibody) and IPI-549 (a phosphoinositide-3-kinase gamma inhibitor) in patients with advanced solid tumors.
Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Merck KGaA.
Trends In The Global Pd-1 & Pd-L1 Inhibitors Market
- Increasing Number Of Collaboration For Combination Therapy
- Designation For The Development Of The Pd-1 And Pd-L1 Inhibitors
Opportunities In The Global Pd-1 & Pd-L1 Inhibitor Market
- Less Number Of Competitors
- Expected Launch Of Phase III Drug Candidate
Factors Driving Growth Of The Market And Its Impact On Market Forecast
- Strong Pipeline
- Increased Investment And Funding
- Improved Safety And Efficacy
- Technological Advancements And Innovations
- High Prevalence Of Cancer
- Impact Analysis Of Drivers On Market Forecast
Factors Hindering The Growth Of The Market And Its Impact On Market Forecast
- High Cost Of Research And Therapy
- Side Effects And Toxicity
- Stringent And Time Consuming Regulatory Process
- Impact Analysis Of Restraints On Market Forecast
Company Profiles And Strategic Developments
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Novartis Ag
- Bristol-Myers Squibb Company
- Astrazeneca Plc
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceutical, Inc.
- Merck Kgaa
- Merck & Co., Inc.
For more information about this report visit http://www.researchandmarkets.com/research/dnnw73/global_programmed